New drug for treating chest pain approved by Health Canada


A new treatment option has been approved for the symptomatic treatment of patients with stable angina pectoris.

Angina pectoris, in layman's terms, is chest pain associated with coronary heart disease--it occurs when the heart isn't getting enough oxygen, normally due to narrowing or blockage of an artery.

Fortunately for those who are not receptive to first-line antianginal therapies, such as beta-blockers and calcium antagonists, a new drug from Mississauga-based KYE Pharmaceuticals Inc. has been approved by Health Canada.

The drug, CORZYNA provides a dose of ranolazine through extended-release tablets--ranolazine has been available internationally for well over a decade.

The drug is projected to hit the Canadian market by the spring of 2021.

“KYE is extremely pleased to be able to bring this important new class of an anti-anginal medication to Canadian patients and healthcare professionals” Doug Reynolds, president of KYE, said in a news release.

“This is a highlight for KYE and for those Canadian patients suffering from recurrent angina episodes," he continued.

Your Comments